Co-administering Melatonin With an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-Positive Breast Cancer

By Balasunder R Dodda, Corry D Bondi, Mahmud Hasan, William P Clafshenkel, Katie M Gallagher, Mary P Kotlarczyk, Shalini Sethi , Ethan Buszko, Jean J Latimer, J Mark Cline, Paula A Witt-Enderby, Vicki L Davis


Melatonin has numerous anti-cancer properties reported to influence cancer initiation, promotion, and metastasis. With the need for effective hormone therapies (HT) to treat menopausal symptoms without increasing breast cancer risk, co-administration of nocturnal melatonin with a natural, low-dose HT was evaluated in mice that develop primary and metastatic mammary cancer. Individually, melatonin (MEL) and estradiol-progesterone therapy (EPT) did not significantly affect mammary cancer development through age 14 months, but, when combined,... (Read Full Article)


Read the Full Article